Citation Impact
Citing Papers
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein
2000 StandoutNobel
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
2005 StandoutNobel
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Cardiopulmonary function in two human disorders of the hypoxia‐inducible factor (HIF) pathway: von Hippel‐Lindau disease and HIF‐2α gain‐of‐function mutation
2011 StandoutNobel
Analysis of von Hippel—Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
2002
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
The pressure rises: update on the genetics of phaeochromocytoma
2002
Genetics, epigenetics and pharmaco‐(epi)genomics in angiogenesis
2008
Von Hippel‐Lindau gene alterations in sporadic benign and malignant pheochromocytomas
2003
Spermidine/Spermine-N1-Acetyltransferase 2 Is an Essential Component of the Ubiquitin Ligase Complex That Regulates Hypoxia-inducible Factor 1α
2007 StandoutNobel
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
2000
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
2001
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
von Hippel-Lindau Disease
1997 StandoutNobel
The Epigenomics of Cancer
2007 Standout
Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
2013
Hypermethylation of tumor suppressor genes in cancer
1999
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Epigenetics in Cancer
2008 Standout
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
Human Exonuclease I Is Required for 5′ and 3′ Mismatch Repair
2002 StandoutNobel
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
A clinical and molecular genetic analysis of solitary ocular angioma
1999
von Hippel-Lindau disease
2003 Standout
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma
2008
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Cancer-epigenetics comes of age
1999 Standout
Genome maintenance mechanisms for preventing cancer
2001 StandoutNature
DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development
1999 Standout
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis
2001
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas1
2000
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
2016 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system
2001
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesis
1998
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.
1996
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
von Hippel-Lindau Disease
2006 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Mutations in the VHL gene in sporadic apparently congenital polycythemia
2003
The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2
1997 Standout
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
1998 Standout
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function
1998
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
1998
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.
1996
The Role of DNA Methylation in Mammalian Epigenetics
2001 StandoutScience
The Neuroimaging and Clinical Spectrum of Neurofibromatosis 2
1996
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti–vascular endothelial growth factor receptor therapy
2002
Endogenous von Hippel-Lindau tumor suppressor protein regulates catecholaminergic phenotype in PC12 cells.
2002
Biallelic inactivation of hMLH 1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
1998 StandoutNobel
HIF-1 and human disease: one highly involved factor
2000 StandoutNobel
Expression of hypoxia-inducible factor 1? in brain tumors
2000 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Works of F Resche being referenced
Germline mutation profile of theVHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma
1998
Screening for germ‐line mutations in the NF2 Gene
1995
Von Hippel-Lindau disease
2004
Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
1995
Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease
2000
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
1997
Pheochromocytoma as the first manifestation of von Hippel-Lindau disease.
1994